Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) EBITDA (2023 - 2025)

Historic EBITDA for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to -$9.3 million.

  • Mereo BioPharma's EBITDA fell 1870.45% to -$9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.4 million, marking a year-over-year decrease of 1879.59%. This contributed to the annual value of -$44.6 million for FY2024, which is 7660.31% down from last year.
  • Per Mereo BioPharma's latest filing, its EBITDA stood at -$9.3 million for Q3 2025, which was down 1870.45% from -$8.0 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma's EBITDA registered a high of -$351000.0 during Q2 2023, and its lowest value of -$14.8 million during Q4 2024.
  • For the 3-year period, Mereo BioPharma's EBITDA averaged around -$8.8 million, with its median value being -$9.3 million (2025).
  • As far as peak fluctuations go, Mereo BioPharma's EBITDA plummeted by 339002.85% in 2024, and later surged by 3494.69% in 2025.
  • Over the past 3 years, Mereo BioPharma's EBITDA (Quarter) stood at -$5.0 million in 2023, then tumbled by 195.47% to -$14.8 million in 2024, then skyrocketed by 37.18% to -$9.3 million in 2025.
  • Its last three reported values are -$9.3 million in Q3 2025, -$8.0 million for Q2 2025, and -$9.3 million during Q1 2025.